June 12, 2019
8560 Progress Place
Frederick, Maryland 21702
Richard Bendis, President & CEO
BioHealth Innovation

“FREDERICK, A KEYPLAYER IN THE BIOHEALTH CAPITAL REGION”
Welcome to the

Our Goal:
To become a Top 3 BioHealth Hub by 2023

www.biohealthcapital.com
Top 10 U.S. Biopharma Clusters

Ranking Based on Five Criteria:  

1. NIH Funding  
2. Venture Capital Funding  
3. Patents  
4. Lab Space  
5. Jobs

1. Boston / Cambridge, MA  
2. San Francisco Bay Area  
3. New York/New Jersey  
4. Maryland / Virginia / DC Metro  
5. San Diego  
6. Greater Philadelphia  
7. Los Angeles / Orange County  
8. Raleigh-Durham, NC (inc. Research Triangle Park, NC)  
9. Seattle  
10. Chicagoland
BioHealth Capital Region is on the way to achieving its stated goal of growing the Maryland / Virginia / Washington, D.C. region into a top-three cluster by 2023. In addition to longtime anchors such as the NIH and FDA, and academic institutions led by the Johns Hopkins University and University of Maryland system, the life sciences have seen expanded business activity and support from officials led by Virginia Gov. Ralph Northam (D) and Maryland Gov. Larry Hogan (R). The region is already third in NIH funding (3103 awards totaling $1.456 billion), 42% of which was awarded to Johns Hopkins ($605.781 million). Three U. of Maryland schools (Baltimore, College Park, and Baltimore County) garnered a combined $214.528 million.

BioHealth Capital is also third in patents (4943, just 32 ahead of San Diego), and fourth in lab space (with 22.5 million square feet according to Rockville, MD-based Scheer Partners, which measures the entire region [vs. JLL’s 9.5 million for “suburban Maryland”]). VC has improved from sixth in 2016: PwC/CB Insights ranks the region fourth with $944.07 million in 44 deals, but JLL tallies $1.1 billion, good enough for third. This year’s VC includes the $250 million Series A financing completed in February by Viela Bio in Gaithersburg, MD, formed when AstraZeneca spun off six pipeline candidates of its Gaithersburg-based MedImmune subsidiary. However, BioHealth Capital appears to lag in employment: JLL has the region ninth with 41,322 jobs, though Battelle in June showed a more respectable 63,287 jobs as of 2016, good for sixth place.
The Growth of the “BioHealth” Brand

BioHealth Innovation

BioHealth Capital Region

Office of Biohealth – Maryland Department of Commerce

BioHealth Capital Region – Genetic Engineering News

Institute for Biohealth Innovation – George Mason

Wisconsin’s Biohealth Industry

Women in Biohealth – U.W. Madison

Growing Biohealth Cluster – Ohio

Luxembourg Biohealth Cluster

South Korea Biohealth Industry

IT ALL STARTED HERE!
2019 BioHealth Capital Regional Forum

1,129 Registrants
50 Sponsors
Top 3 by 2023

Showcasing accomplishments and opportunities for the BioHealth Capital Region

www.bhcrforum.com

April 8 + 9, 2019
One MedImmune Way, Gaithersburg, MD 20878
VC Funding in the BioHealth Capital Region

Average deal size has climbed from $11.5 million to $14.8 million in 2018 as overall volume reached over $700 million.

Source: JLL Research
<table>
<thead>
<tr>
<th>Company</th>
<th>Type</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arcellx</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $26M to date</td>
</tr>
<tr>
<td>Graybug Vision</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $49M to date</td>
</tr>
<tr>
<td>NextCure</td>
<td>Technology from Yale</td>
<td>Raised $67M to date</td>
</tr>
<tr>
<td>Sonavex</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $6.6M to date</td>
</tr>
<tr>
<td>BeneVir</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $154M to date</td>
</tr>
<tr>
<td>PGD</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $99.3M to date</td>
</tr>
<tr>
<td>SpringWorks therapeutics</td>
<td>Pfizer spin-out</td>
<td>Raised $103M to date</td>
</tr>
<tr>
<td>Dracen Pharmaceuticals</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $40M to date</td>
</tr>
<tr>
<td>Neuraly Inc.</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $36M to date</td>
</tr>
<tr>
<td>NexImmune</td>
<td>Johns Hopkins spin-out</td>
<td>Raised $28.2M to date</td>
</tr>
<tr>
<td>GlycoMimetics, Inc.</td>
<td>MedImmune/AstraZeneca spin-out</td>
<td>Raised $119M to date</td>
</tr>
<tr>
<td>Precision for Medicine</td>
<td>MedImmune/AstraZeneca spin-out</td>
<td>Raised $275M to date</td>
</tr>
<tr>
<td>RegenxBio</td>
<td>Pfizer spin-out</td>
<td>Raised $100M to date</td>
</tr>
<tr>
<td>Vielabio</td>
<td>MedImmune/AstraZeneca spin-out</td>
<td>Raised $250M to date</td>
</tr>
<tr>
<td>WindMIL Therapeutics</td>
<td>MedImmune/AstraZeneca spin-out</td>
<td>Raised $32.5M to date</td>
</tr>
</tbody>
</table>
While ranked 4th nationally in extramural research, the region leads when combined with NIH’s intramural research, which has over $3 billion of funding per year and is conducted by nearly 6,000 scientists primarily in Bethesda, MD.
Biohealth Asking Rents

Suburban Maryland and the region offer competitive rates for life sciences space when compared against other top-tier biohealth clusters.

Source: JLL Research
Biohealth Capital Region Historical Vacancy

Vacancy in Suburban Maryland has stabilized at record low levels.

Source: JLL Research
## BIOHEALTH SUCCESS IN THE BIOHEALTH CAPITAL REGION
Maryland, Virginia, and the District of Columbia

### Breaking News
NextCure raises $86.25M in IPO. Siranomics closes $47M Series C financing.

<table>
<thead>
<tr>
<th>Company</th>
<th>Funding Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aledade</td>
<td>$56,150,000 in Venture Capital in January 2019</td>
</tr>
<tr>
<td>Altimmune</td>
<td>$56,000,000 in financing in March 2019</td>
</tr>
<tr>
<td>Arentage</td>
<td>Raises $150,000,000 in Venture Capital in July 2018</td>
</tr>
<tr>
<td>Autolus</td>
<td>Raises $150,000,000 in IPO on NASDAQ; relocates US headquarters to Rockville, MD in June 2018</td>
</tr>
<tr>
<td>BeneVir</td>
<td>Agreement to be acquired by Janssen for up to $1,040,000,000 in May 2018</td>
</tr>
<tr>
<td>Catalent</td>
<td>Acquired Paragon Biosciences for $1,200,000,000 in April 2019</td>
</tr>
<tr>
<td>Danaher</td>
<td>Acquired Biopharma Business of GE Life Sciences for $214,000,000 in February 2019</td>
</tr>
<tr>
<td>Emergent</td>
<td>$1,000,000,000 plus in- pharma acquisitions in 2018 [PaxVax and Ademp Pharma]</td>
</tr>
<tr>
<td>Emirates</td>
<td>Receives equity deal with Beltman Capital in March 2019</td>
</tr>
<tr>
<td>GlycoMimetics, Inc.</td>
<td>Raises $110,000,000 in Venture Capital in June 2018</td>
</tr>
<tr>
<td>Kite Pharma</td>
<td>Kite expands in Maryland with 26,000 SF cell therapy facility to support CRADA agreement with NCI in May 2018</td>
</tr>
<tr>
<td>MacroGenics</td>
<td>Raises $110,000,000 in Venture Capital in February 2019</td>
</tr>
<tr>
<td>Mimetis</td>
<td>$20,500,000 in Venture Capital in April 2018</td>
</tr>
<tr>
<td>NextImmune</td>
<td>$23,050,000 Series A spin-out of Xena Networks in January 2018</td>
</tr>
<tr>
<td>Osiris</td>
<td>Acquired by Smith &amp; Nephew in transaction valued at $469,000,000 in April 2019</td>
</tr>
<tr>
<td>Regeneron Biotech</td>
<td>$201,800,000 IPO projection contingent on market conditions in August 2018</td>
</tr>
<tr>
<td>Senseonics</td>
<td>$149,500,000 post IPO equity in March 2019</td>
</tr>
<tr>
<td>Stryker</td>
<td>Acquired K2M in transaction valued at $1,400,000,000 in September 2018</td>
</tr>
<tr>
<td>Supernus</td>
<td>Acquires Biscayne in transaction valued at $185,000,000 in September 2018</td>
</tr>
<tr>
<td>VienBio</td>
<td>Raises $357,000,000 Series A spin-out of AstraZeneca in March 2019</td>
</tr>
<tr>
<td>WindMIL</td>
<td>$32,500,000 Series B in June 2018</td>
</tr>
</tbody>
</table>

---

**Note:** The information is a snapshot of successful funding and acquisitions in the BioHealth Capital Region as of the date of the report.
State of Maryland: Federal & University Resources

- Population: 5.9 million people
- 59 Federal Laboratories, Centers, & Institutes in Maryland
- Maryland Federal R&D investment exceeding $12 billion annually

JHU and USM represent another $3.5 billion in annual R&D
Unrivaled Research Assets | Unfulfilled Commercial Promise

800+ BioHealth Companies
Frederick Maryland is Where Cultures Connect

- Business Friendly Environment
- Skilled Workforce & Educational System
- Strategic Location & Access
- From Incubation to Acceleration
Top Bio/Life Science Employers in Frederick

United States Army
Fort Detrick
Veterans Gate

NIH
NATIONAL CANCER INSTITUTE

AstraZeneca

Lonza

Frederick National Laboratory
for Cancer Research

ThermoFisher Scientific

Precision Medicine Group
Frederick County

• Frederick County is home to more than 90 life science companies and research organizations

• Frederick County is home to 10% of all direct private sector life science jobs in Maryland

• Highly specialized in biological product and pharmaceutical manufacturing, biotech R&D and cell/gene therapy

• Major private-sector players in the market include AstraZeneca, Lonza, ThermoFisher and Kite Pharma cell therapy manufacturing facility.

• Ft. Detrick, NCI and Leidos/Frederick National Lab are key anchors and drivers of the life sciences industry

• FITCI – created in 2005 – was recently named one of the top 5 life science incubators in the BioHealth Capital Region – notable graduates include Akonni, Kemp Bio, RoosterBio, BioFactura among many others.
The National Institutes of Health is Open for Business

• The National Institutes of Health (NIH) is the largest basic science research institute in the world.

• NIH’s more than 100 technology transfer professionals help our thousands of researchers – from basic to translational (and yes) to clinical

• NIH’s technology transfer offices are establishing themselves as open for business – as one of the go-to places for the healthcare industry to work with a thought-leader

• The largest provider of direct support in the world – over $30B this fiscal year

• Mission statement - Surprise: it includes accelerating and promoting economic development
Extramural Research

~ 80% of NIH budget
Supporting research worldwide

> 50,000 awards annually
(direct funding)

Academic ↔ NIH
Result: publications

~ 10% of NIH budget
Supporting research by on-site faculty

> 2,000 active collaborations
(indirect funding; cost-sharing)

Industry ↔ NIH
Result: medical solutions to market
What are the Advantages for NIH?

• Access to cutting-edge innovations
• Access to commercial development expertise
• Funds for research project
• Satisfaction of getting medical solutions to patients
NIH Value Proposition

>$1B Product sales from licensed NIH/FDA IP (FY17)

✓ No equity position
✓ 10% overhead rate
✓ Doesn’t take your IP
✓ Validate your technology and/or test in humans
✓ World-renowned researchers and resources
✓ Prestige factor: Collaboration = higher company profile
Current NIH Partners are World-wide, Represent Numerous Stakeholders

Agreement Requests Globally

Requests from Stakeholders
Recent NCI Maryland Success Stories

VERALOX THERAPEUTICS

miRecule microRNA Therapeutics
BioHealth Innovation
Regional Innovation Intermediary

A public-private partnership, serving as an innovation intermediary in the BioHealth Capital Region with a mission to:

- Advance local technologies, assets and resources
- Accelerate innovation
- Globally connect sectors, industries, communities, and markets

- Regionally-oriented
- Private-public partnership, 501(c)(3) nonprofit
- BioHealth Innovation Management, a for-profit subsidiary
- Market-driven, private sector-led and funded
- Neither a government initiative, nor a membership organization
Regional BioHealth Ecosystem Partners

ACADEMIA
- Research/T2
- Lifelong Learning
- Economic Development

INDUSTRY
- Profit
- Process
- Product

GOVERNMENT
- Sustainability
- Infrastructure Support
- Economic Policy

FOUNDATIONS/NGOS
- Economic Growth
- Community Investment
- Regional Collaboration

INSEPARABLE MISSIONS
# BHI Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rip Ballou</td>
<td>VP &amp; Head, US R&amp;D Center GSK Vaccines</td>
</tr>
<tr>
<td>Richard A. Bendis</td>
<td>President &amp; CEO BioHealth Innovation, Inc.</td>
</tr>
<tr>
<td>Jarrod Borkat</td>
<td>Vice President Corporate Strategy Emergent Biosolutions</td>
</tr>
<tr>
<td>Robert Caret, Ph.D.</td>
<td>Chancellor University System of Maryland</td>
</tr>
<tr>
<td>Kenneth Carter, Ph.D.</td>
<td>Chairman Noble Life Sciences</td>
</tr>
<tr>
<td>Christopher Callaghan</td>
<td>Group Vice President, Healthcare Banking M&amp;T Bank</td>
</tr>
<tr>
<td>Ronald J. Daniels</td>
<td>President Johns Hopkins University</td>
</tr>
<tr>
<td>William Hearl, Ph.D.</td>
<td>Founder and CEO Immunomic Therapeutics, Inc.</td>
</tr>
<tr>
<td>Ashish K. Kulkarni, Ph.D</td>
<td>EVP &amp; CTO Avantor</td>
</tr>
<tr>
<td>Dave Lemus</td>
<td>CEO/Principal LEMAX, LLC</td>
</tr>
<tr>
<td>Anne S. Lindblad</td>
<td>President &amp; CEO The Emmes Corporation</td>
</tr>
<tr>
<td>Douglas Liu (Chair)</td>
<td>Senior VP of Global Operations Qiagen</td>
</tr>
<tr>
<td>Joel Marcus</td>
<td>Executive Chairman &amp; Founder Alexandria Real Estate Equities, Inc.</td>
</tr>
<tr>
<td>Beth Meagher</td>
<td>Principal Deloitte Consulting LLP</td>
</tr>
<tr>
<td>Charles Morton</td>
<td>(Secretary) Partner Venable LLP</td>
</tr>
<tr>
<td>David Mott</td>
<td>General Partner New Enterprise Associate:</td>
</tr>
<tr>
<td>Kurt Newman, M.D.</td>
<td>President &amp; CEO Children’s National Medical Center</td>
</tr>
<tr>
<td>John A. Sackett</td>
<td>President Shady Grove Adventist Hospital</td>
</tr>
<tr>
<td>Robert Silverman</td>
<td>Head Externalized Drug Discovery Partnering, Roche</td>
</tr>
<tr>
<td>John Trainer</td>
<td>Vice President and Head Partnering and Strategy AstraZeneca</td>
</tr>
</tbody>
</table>
Research and technologies enter into the pipeline from sources shown on the left and are evaluated by the EIR team. Commercially relevant startups are connected to assistance programs on a case-by-case basis. Once a startup becomes a portfolio company, they gain access to partners and resources.
BHI Technology Focus

- Therapeutics
- Diagnostics
- Medical Devices
- Healthcare Services
- E-Health
- Mobile Health
- Electronic Medical Records
- Health Informatics
- BioHealth
- Cybersecurity
- Personalized Health
- Convergence
Innovation Paradigm Shift

PROOF OF CONCEPT
(Technological Feasibility)
Laboratory
Push
“It Works!”

PROOF OF COMMERCIAL RELEVANCE
(Market Pull)
“It Works To Solve A Problem” “I’ll Buy It”
Investment Conference
October 15 + 16, 2019

INVITATION ONLY

95 Invited Companies
32 Invited Investors

To connect Quality emerging BioHealth companies seeking capital to Investors looking for Quality deals.

SPONSORED BY:

Wilson Sonsini Goodrich & Rosati
BioHealth Innovation
J.P. Morgan
Maryland Department of Commerce
Deloitte
AstraZeneca

For more information contact: BHI@BioHealthInnovation.org
2018 BHCR INVESTMENT CONFERENCE RECAP

95 Invited Companies

AAVogen
Adaptive Phage Therapeutics
Advanced BioNutrition
Akan Biosciences
Algometrix, Inc.
American Gene Technologies
Antidote Therapeutics, Inc.
Anven Biosciences, Inc.
AscelpiX Therapeutics
Asulon Therapeutics Inc.
Atrin Pharmaceuticals
Avant Diagnostics
Avidoe Technologies, Inc.
BioGraph 55, Inc.
Bonumose LLC
BrainScope Company, Inc.
BraneQuest
CARISMA Therapeutics
Cellphire, Inc.
Cellth Systems
Ceres Nanosciences, Inc.
ChromaTan Corp.
CoolTech LLC
CorIT LLC
Creative Bio-Peptides
Cupron Inc.
DermaSensor Inc.
Diffusion Pharmaceuticals Inc.
eKare Inc.
Embody
Empower Telehealth
Enterin Inc.
Euclid Systems Corp.
ExPrimary, Inc.
gel-e, Inc.
Gemstone Biotherapeutics, LLC
Glutaral Medical
Glyscend, Inc.
HeMemeics
HemoShear Therapeutics, LLC
Ikigai Biotech Group Inc.
Immunarray Ltd
Immunologic Therapeutics
Infinite
Integrated BioTherapeutics
KinaRx
Landos Biopharma
LifeSprout, Inc.
Liffey Biotech Ltd.
Mavin Wear Inc.
MDNA Life Sciences
Micro Interventional Devices, Inc.
Mirata Pharmaceuticals
miReucle
Nanochon
Navimize
Neximmune Inc.
NextStep Robotics Inc.
Novodux
Oncoceutics
Opsidio, LLC
Orbit Genomics
Otomagnetics, Inc.
Pepitoligics
Perceptive Navigation, LLC
Remedy Plan Therapeutics
Renalert
Salveo Diagnostics
SciTech Development
Select OcuFLOW, Inc.
Sequella, Inc.
Seraxis Inc
Sisu Global Health Inc.
Sonavex, Inc.
Stuart Therapeutics, Inc.
Surgibox, Inc.
SuviCo, Inc.
TailRx US, Inc.
Teralimmune
Theradaptive
Thermal Gradient
TMPG Health
Trimeric Therapeutics
True Bearing Diagnostics, Inc.
TruGenomix Health, Inc.
VakSea
Veralox Therapeutics, Inc.
Weinberg Medical Physics, Inc.
Western Oncolytics Ltd
WindMIL Therapeutics
ZyGood LLC

32 Invited Investors

AbbVie Ventures
Alexandria Real Estate Equities
Arch Venture Partners
Asahi Kasei Corporation
Brace Pharma Capital
CrossRoads Capital Strategy
Epidarex Capital
Emergent BioSolutions
Falls River Group
Hatteras Venture Partners
Illuina Ventures
Inova Personalized Health Accelerator
Intermountain Healthcare Ventures
Johnson & Johnson
J.P. Morgan
Keiretsu Forum
Leukemia & Lymphoma Society Venture Arm
LyfeCapital
Maryland Venture Fund (TEDCO)
Middleland Capital (VTC Innovation Fund)
MPM Capital
New Enterprise Associates
Ocean Capital
Orbimed
Predictive Tech Group
Prevail Partners
Quan Capital
Sands Capital Management
Sun Pharma
Taiho Ventures, LLC
Taiwania Capital
Tosoh USA
NIH Partnership Agreements

NIH Consulting Entrepreneur Services Contract for 6 NIH Entrepreneurs-in- Residence

PIA between BHI and NIH’s Office of Technology Transfer (OTT) that supports the 27 NIH institutes’ $3 billion intramural research and the Food and Drug Administration to **promote and foster cooperative research and accelerate technology commercialization** among NIH/FDA, businesses, and universities.
BHI Team

**Rich Bendis**
Founder & CEO, BHI
40+ years experience:
Innovation America &
Innovation Philadelphia,
Marion Laboratories,
Continental Healthcare Systems,
Kimberley Services,
Texas Instruments,
Polaroid,
Quaker Oats

**Albine Martin, Ph.D.**
Entrepreneur-in-Residence
Johns Hopkins University
30+ years industry experience:

**Ethel Rubin, Ph.D.**
Entrepreneur-in-Residence, NIH
10+ years industry experience:

**Stephen Wolpe, Ph.D.**
Entrepreneur-in-Residence, NIH
25+ years industry experience & as an independent biotechnology consultant

**Luis Gutierrez, Ph.D.**
Entrepreneur-in-Residence, NIH
20+ years industry experience:

**John Sullivan, MBA**
Entrepreneur-in-Residence, NIH
24+ years industry, consulting, and VC experience:

**Anthony Saleh, Ph.D.**
Associate EIR, BHI

**Judy Costello**
Executive Director
BioHealth Innovation
25+ years in economic development in Northern VA, Washington DC, and MD
BHI Federal Funding Assistance

- $3.5 billion annual United States Government program coordinated by the Small Business Administration provides grants or contracts to small businesses to spur technological innovation
- Grants awarded in 3 phases between $100,000 and $2.0 million
- Non-dilutive

Value Chain of Assistance

- Funding Concept Review
  Ensure Appropriateness for the Federal Agency
- Application Technical Support
  Guidance through Federal Registration Process
- Proposal Development
  In-Kind Guidance on Proposal Best Practices
- Funding for High-Quality Proposals
  Intensive Support with Professional Consultant

Funding Agencies

$28.5M Funding awarded | 45 wins of 97 SBIR and STTR submissions | 46% success rate
BHI offers international companies the perfect starting point to create US-based subsidiaries. Soft landing companies are given access to BHI's extensive business resources including Business Development & Sales, Entrepreneurs-in-Residence (EIR), Financial, Grant Writing/SBIR Federal Funding Assistance, Human Resources, Incubation/Site Location, Legal - Corporate & Intellectual Property, Marketing & Promotion, Market Research, Network & Connections, Regulatory & Preclinical /Clinical, and Reimbursement.
Websites, News and More

**BHI Website**

The BHI website has news, an events calendar, research publications, regional organization feature stories and resources for the biohealth industry.

www.biohealthinnovation.org

**BioHealth Capital Region**

The BHCR website highlights the region’s biohealth news, stories, trends and events.

www.biohealthcapital.com

**BioTalk**

Rich Bendis, hosts BioTalk — conversations with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry.

**BHI News**

BHI’s weekly e-newsletter highlights the Central Maryland region’s news articles, national biohealth trends and feature stories.

www.biohealthinnovation.org/news

**BHCR News**

BHCR News is a monthly publication that highlights industry news throughout the region.
Regulatory Strategies for Emerging Healthcare/Life Science Companies:
Everything You Need to Know, but Didn’t Know to Ask!

June 19, 2019 6:00pm-
8:30pm
Hood College
401 Rosemont Avenue
Frederick, MD 21701

Mukesh Kumar, PhD
Chief Executive Officer at Brij Strategic Consultations
SAVE THE DATE  October 10th, 2019

6th BioBowl

Come join us for the 6th Annual BioBowl!

You and your company team will be competing against other biotech firms to win the coveted BioBowl Trophy and bragging rights! ...Until next year

Date  Thursday, October 10th, 2019
Time  4:00 - 6:30 PM (TBC)
Location  Bowlmor – 15720 Shady Grove Rd
           Gaithersburg, MD 20877

Invitation to follow.

Hosted By: BioHealth Innovation & AstraZeneca

Founding Member

BIOHEALTH CAPITAL REGION
Advancing Science. Accelerating Innovation.
SAVE THE DATE

BioHealth Capital Regional Forum
April 15 + 16, 2020
1 MedImmune Way, Gaithersburg, MD
• BHCR is “OPEN FOR BUSINESS”

• Maryland is “OPEN FOR BUSINESS”

• City & County of Frederick are “OPEN FOR BUSINESS”

• National Cancer Institute is “OPEN FOR BUSINESS”

• Frederick National Laboratory is “OPEN FOR BUSINESS”

• BioHealth Innovation is “OPEN FOR BUSINESS”
BHI Contact

1 Church Street, Suite 801
Rockville, MD 20850
(301) 637-7950

info@biohealthinnovation.org

www.biohealthinnovation.org